High BIN1 expression has a favorable prognosis in malignant pleural mesothelioma and is associated with tumor infiltrating lymphocytes

Malignant pleural mesothelioma (MPM) is an aggressive and invariably fatal cancer of the pleural surface that is associated with asbestos exposure [1]. MPM is usually detected at an advanced stage, therefore treatment options are limited to systemic chemotherapy with cisplatin and pemetrexed as the mainstay of palliative treatment for most patients [2]. Prognosis is generally poor for MPM, with a median survival of 12 months in patients treated with pemetrexed and cisplatin chemotherapy [3] but can be very variable, with around 5% of patients surviving more than 5 years [4].

Source: Lung Cancer - February 7, 2019 Category: Cancer & Oncology Authors: Tamkin Ahmadzada, Kenneth Lee, Candice Clarke, Wendy A Cooper, Anthony Linton, Brian McCaughan, Rebecca Asher, Stephen Clarke, Glen Reid, Steven Kao Source Type: research